Our results revealed that post-stroke EE treatment promoted functional recovery in a pro-angiogenesis manner through astrocytic IL-17A, which might promote CD34 and VEGF expression during the recovery phase of stroke. This evidence concerns the gene VEGFA and stroke disorder.